Form 4: Johnson & Johnson Executive VP, CFO Joseph J. Wolk Reports Changes in Beneficial Ownership
SEC Form 4
Executive VP and CFO of Johnson & Johnson, Joseph J. Wolk, reports changes in beneficial ownership of company stock through gifts and holdings in a spousal lifetime access trust and 401k.
Summary
- On May 22, 2024, Joseph J. Wolk, Executive VP and CFO of Johnson & Johnson, reported a transaction involving common stock.
- Mr. Wolk disposed of 55 shares of common stock as a gift.
- On October 17, 2024, Mr. Wolk reported a gift of 68,835 shares of common stock.
- On October 17, 2024, Mr. Wolk acquired 68,835 shares of common stock.
- Following these transactions, Mr. Wolk directly owns 0 shares and indirectly owns 68,835 shares through a Spousal Lifetime Access Trust (SLAT) and 2,095 shares through a 401k.
- The shares held in the 401k include shares accrued due to dividend reinvestment as of January 31, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing changes in stock ownership, which carries a neutral sentiment.
Industry Context
This is a routine filing related to changes in beneficial ownership by a company executive, which is common for publicly traded companies like Johnson & Johnson. It provides transparency into the executive's holdings and transactions in the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for executives at publicly traded companies like Johnson & Johnson, similar to filings made by executives at companies like Pfizer (PFE), Merck (MRK), and AbbVie (ABBV).
- The reporting requirements are governed by Section 16(a) of the Securities Exchange Act of 1934, ensuring transparency in executive stock transactions across the industry.
- Executives often use trusts like SLATs for estate planning purposes, a common practice also seen among executives at comparable companies.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the stock transactions of a key executive.
- The transactions themselves may have a negligible impact on the company's operations or financial performance.
Key Dates
| Date | Description |
|---|---|
| 01/31/2024 | Most recent reporting date for Johnson & Johnson Savings Plan, reflecting dividend reinvestment in the Johnson & Johnson Stock Fund. |
| 05/22/2024 | Date of transaction where Joseph J. Wolk disposed of 55 shares of common stock as a gift. |
| 10/17/2024 | Date of transaction where Joseph J. Wolk gifted 68,835 shares of common stock. |
| 10/17/2024 | Date of transaction where Joseph J. Wolk acquired 68,835 shares of common stock. |
| 10/21/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.